Immunoconjugate Anticancer Therapeutics

  • Serengulam V. Govindan
  • David M. Goldenberg
Part of the Macromolecular Anticancer Therapeutics book series (CDD&D)


Immunoconjugate therapy has entered the mainstream of cancer management with the regulatory approval and the bench to bedside transition of three antibody conjugates for lymphoma and leukemia. A number of antibody conjugates of radionuclides, drugs, and protein toxins are in various stages of clinical development. These treatments are relatively more effective in hematological cancers than in solid cancers and are generally more effective in minimal disease, in the adjuvant setting, and as combination therapies with nonoverlapping toxicities. Pretargeted radioimmunotherapy, with its superiority to direct radioimmunotherapy documented in preclinical studies, is being actively pursued to improve efficacy and minimize toxicity. Emerging approaches to the design of conjugates with defined structure and stoichiometry provide opportunities to expand the therapeutic window. In this category, the “dock-and-lock” (DNL) technology enables the facile assembly of multifunctional structures of defined composition, combining the targeting and the therapeutic moieties site specifically. Recent advances in the use of different classes of immunoconjugates are described.


Autologous Stem Cell Transplantation Anaplastic Large Cell Lymphoma Gemtuzumab Ozogamicin Pokeweed Antiviral Protein Anchor Domain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



anaplastic astrocytoma


anchoring domain


acute myeloid leukemia


anaplastic oligodendroglioma


dimerization and docking domain




1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid


diphtheria toxin


diethylenetriaminepentaacetic acid


glioblastoma multiforme


gemtuzumab ozogamicin






monoclonal antibodies


maytansine and monomethyl auristatin E


medullary thyroid cancer


maximum-tolerated dose


non-Hodgkin’s lymphoma


overall survival


Pseudomonas exotoxin


progression-free survival


autologous stem cell transplantation




rituximab-chemotherapy combination




single photon emission computed tomography


Total-body irradiation


  1. 1.
    Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226–243CrossRefPubMedGoogle Scholar
  2. 2.
    Rossi EA, Goldenberg DM, Cardillo TM et al. (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 103:6841–6846CrossRefPubMedGoogle Scholar
  3. 3.
    Gold DV, Goldenberg DM, Karacay H et al. (2008) A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 68:4819–4826CrossRefPubMedGoogle Scholar
  4. 4.
    Goldenberg DM, Rossi EA, Sharkey RM et al. (2008) Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49:158–163CrossRefPubMedGoogle Scholar
  5. 5.
    Sharkey RM, Goldenberg DM (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46(suppl 1):115S–127SPubMedGoogle Scholar
  6. 6.
    Sharkey RM, Goldenberg DM (2006) Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest 24:82–97CrossRefPubMedGoogle Scholar
  7. 7.
    Sharkey RM, Burton J, Goldenberg DM (2005) Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal. Expert Rev Clin Immunol (–62 CrossRefPubMedGoogle Scholar
  8. 8.
    Govindan SV, Goldenberg DM, Hansen HJ et al. (2000) Advances in the use of monoclonal antibodies in cancer radiotherapy. Pharm Sci Technolo Today 3:90–98CrossRefPubMedGoogle Scholar
  9. 9.
    Chong HS, Ma X, Le T et al. (2008) Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J Med Chem 51:118–125CrossRefPubMedGoogle Scholar
  10. 10.
    Stein R, Govindan SV, Mattes MJ et al. (2003) Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 63:111–118PubMedGoogle Scholar
  11. 11.
    Shankar S, Vaidyanathan G, Affleck D et al. (2003) N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs. Bioconjug Chem 14:331–341CrossRefPubMedGoogle Scholar
  12. 12.
    Zalutsky MR, Pozzi OR (2004) Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 48:289–296PubMedGoogle Scholar
  13. 13.
    Mulford DA, Scheinberg DA, Jurcic JG (2005) The promise of targeted α-particle therapy. J Nucl Med 46(Suppl 1):199S–204SPubMedGoogle Scholar
  14. 14.
    Mattes MJ (2002) Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 94:1215–1223CrossRefPubMedGoogle Scholar
  15. 15.
    Welt S, Scott AM, Divgi CR et al. (1996) Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14:1787–1797PubMedGoogle Scholar
  16. 16.
    Schubiger PA, Alberto R, Smith A (1996) Vehicles, chelators, and radionuclides: choosing the “building blocks” of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7:165–179CrossRefPubMedGoogle Scholar
  17. 17.
    Srivastava S, Dadachova E (2001) Recent advances in radionuclide therapy. Semin Nucl Med 31:330–341CrossRefPubMedGoogle Scholar
  18. 18.
    Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488–499CrossRefPubMedGoogle Scholar
  19. 19.
    Fink-Bennett DM, Thomas K (2003) 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Nucl Med Technol 31:61–68PubMedGoogle Scholar
  20. 20.
    Wahl RL (2005) Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J Nucl Med 46(1):128S–140SPubMedGoogle Scholar
  21. 21.
    Witzig TE, Gordon LI, Cabanillas F et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463CrossRefPubMedGoogle Scholar
  22. 22.
    Davis TA, Kaminski MS, Leonard JP et al. (2004) The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10:7792–7798CrossRefPubMedGoogle Scholar
  23. 23.
    Gordon LI, Witzig T, Molina A et al. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5:98–101CrossRefPubMedGoogle Scholar
  24. 24.
    Kaminski MS, Tuck M, Estes J et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449CrossRefPubMedGoogle Scholar
  25. 25.
    Press OW, Unger JM, Braziel RM et al. (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143–4149CrossRefPubMedGoogle Scholar
  26. 26.
    Liu SY, Eary JF, Petersdorf SH et al. (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270–3278PubMedGoogle Scholar
  27. 27.
    Press OW, Eary JF, Gooley T et al. (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934–2942PubMedGoogle Scholar
  28. 28.
    Nademanee A, Forman S, Molina A et al. (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896–2902CrossRefPubMedGoogle Scholar
  29. 29.
    Linden O, Hindorf C, Cavallin-Stahl E et al. (2005) Dose-fractionated radioimmunotherapy in non-Hodgkin’s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 11:5215–5222CrossRefPubMedGoogle Scholar
  30. 30.
    Griffiths GL, Govindan SV, Sharkey RM et al. (2003) 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin’s lymphoma. J Nucl Med 44:77–84PubMedGoogle Scholar
  31. 31.
    Mattes MJ et al. (2008) Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 14(19):6154–6160CrossRefPubMedGoogle Scholar
  32. 32.
    Sharkey RM, Karacay H, Richel H et al. (2003) Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 9:3897S–3913SPubMedGoogle Scholar
  33. 33.
    Sharkey RM, Karacay H, Litwin S et al. (2008) Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin’s lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 68:5282–5290CrossRefPubMedGoogle Scholar
  34. 34.
    Green DJ, Pagel JM, Pantelias A et al. (2007) Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res 13:5598s-5603sCrossRefPubMedGoogle Scholar
  35. 35.
    Weiden PL, Breitz HB (2001) Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL). Crit Rev Oncol Hematol 40:37–51CrossRefPubMedGoogle Scholar
  36. 36.
    Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693–713PubMedGoogle Scholar
  37. 37.
    Jurcic JG, Larson SM, Sgouros G et al. (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100:1233–1239PubMedGoogle Scholar
  38. 38.
    Pagel JM, Appelbaum FR, Eary JF et al. (2006) 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107:2184–2191CrossRefPubMedGoogle Scholar
  39. 39.
    Zhang M, Yao Z, Garmestani K et al. (2002) Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 100:208–216CrossRefPubMedGoogle Scholar
  40. 40.
    Liersch T, Meller J, Kulle B et al. (2005) Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 23:6763–6770CrossRefPubMedGoogle Scholar
  41. 41.
    Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM (2007) Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 14:2577–2590CrossRefPubMedGoogle Scholar
  42. 42.
    Ychou M, Azria D, Menkarios C et al. (2008) Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res 14:3487–3493CrossRefPubMedGoogle Scholar
  43. 43.
    Epenetos AA, Hird V, Lambert H et al. (2000) Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10:44–46CrossRefPubMedGoogle Scholar
  44. 44.
    Grana C, Chinol M, Robertson C et al. (2002) Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86:207–212CrossRefPubMedGoogle Scholar
  45. 45.
    Gold DV, Schutsky K, Modrak D (2003) Low-dose radioimmunotherapy (90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 9:3929S–3937SPubMedGoogle Scholar
  46. 46.
    Burke PA, DeNardo SJ, Miers LA et al. (2002) Combined modality radioimmunotherapy: promise and peril. Cancer 94:1320–1331CrossRefPubMedGoogle Scholar
  47. 47.
    Blumenthal RD, Leone E, Goldenberg DM et al. (2004) An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer 108:293–300CrossRefPubMedGoogle Scholar
  48. 48.
    Zalutsky MR, Reardon DA, Akabani G et al. (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49:30–38CrossRefPubMedGoogle Scholar
  49. 49.
    Reardon DA, Akabani G, Coleman RE et al. (2002) Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389–1397CrossRefPubMedGoogle Scholar
  50. 50.
    Riva P, Franceschi G, Arista A et al. (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80:2733–2742CrossRefPubMedGoogle Scholar
  51. 51.
    Chatal JF, Campion L, Kraeber-Bodere F et al. (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705–1711CrossRefPubMedGoogle Scholar
  52. 52.
    Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41:98–107CrossRefPubMedGoogle Scholar
  53. 53.
    Trouet A, Masquelier M, Baurain R et al. (1982) A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci USA 79:626–629CrossRefPubMedGoogle Scholar
  54. 54.
    Dubowchik GM, Firestone RA, Padilla L et al. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13:855–869CrossRefPubMedGoogle Scholar
  55. 55.
    Berger MS, Leopold LH, Dowell JA et al. (2002) Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs 20:395–406CrossRefPubMedGoogle Scholar
  56. 56.
    Hamann PR, Hinman LM, Hollander I et al. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13:47–58CrossRefPubMedGoogle Scholar
  57. 57.
    Linenberger ML (2005) CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19:176–182CrossRefPubMedGoogle Scholar
  58. 58.
    DiJoseph JF, Armellino DC, Boghaert ER et al. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807–1814CrossRefPubMedGoogle Scholar
  59. 59.
    DiJoseph JF, Goad ME, Dougher MM et al. (2004) Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 10:8620–8629CrossRefPubMedGoogle Scholar
  60. 60.
    Jedema I, Barge RM, van der Velden VHJ et al. (2004) Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18:316–325CrossRefPubMedGoogle Scholar
  61. 61.
    Boghaert ER, Khandke K, Sridharan L et al. (2006) Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 28:675–684PubMedGoogle Scholar
  62. 62.
    Trail PA, Willner D, Lasch SJ et al. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212–215CrossRefPubMedGoogle Scholar
  63. 63.
    Tolcher AW, Sugarman S, Gelmon KA et al. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17: 478–484PubMedGoogle Scholar
  64. 64.
    Hansen HJ, Ong GL, Diril H et al. (1996) Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 320 (Pt 1):293–300PubMedGoogle Scholar
  65. 65.
    Griffiths GL, Mattes MJ, Stein R et al. (2003) Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 9:6567–6571PubMedGoogle Scholar
  66. 66.
    Sapra P, Stein R, Pickett J et al. (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 11: 5257–5264CrossRefPubMedGoogle Scholar
  67. 67.
    Liu C, Tadayoni BM, Bourret LA et al. (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 93:8618–8623CrossRefPubMedGoogle Scholar
  68. 68.
    Tolcher AW, Ochoa L, Hammond LA et al. (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21:211–222CrossRefPubMedGoogle Scholar
  69. 69.
    Greenfield L, Bloch W, Moreland M (1990) Thiol-containing cross-linking agent with enhanced steric hindrance. Bioconjug Chem 1:400–410CrossRefPubMedGoogle Scholar
  70. 70.
    Erickson HK, Park PU, Widdison WC et al. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426–4433CrossRefPubMedGoogle Scholar
  71. 71.
    Kovtun YV, Audette CA, Ye Y et al. (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214–3221CrossRefPubMedGoogle Scholar
  72. 72.
    Doronina SO, Toki BE, Torgov MY et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784CrossRefPubMedGoogle Scholar
  73. 73.
    Francisco JA, Cerveny CG, Meyer DL et al. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465CrossRefPubMedGoogle Scholar
  74. 74.
    Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154–169CrossRefPubMedGoogle Scholar
  75. 75.
    Doronina SO, Bovee TD, Meyer DW et al. (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19(10):1960–1963 doi: 10.1021/bc800289aCrossRefPubMedGoogle Scholar
  76. 76.
    Doronina SO, Mendelsohn BA, Bovee TD et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114–124CrossRefPubMedGoogle Scholar
  77. 77.
    Hamblett KJ, Senter PD, Chace DF et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063–7070CrossRefPubMedGoogle Scholar
  78. 78.
    Walker MA, Dubowchik GM, Hofstead SJ et al. (2002) Synthesis of an immunoconjugate of camptothecin. Bioorg Med Chem Lett 12:217–219CrossRefPubMedGoogle Scholar
  79. 79.
    Moon SJ, Govindan SV, Cardillo TM et al. (2008) Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 51: 6916–6926CrossRefPubMedGoogle Scholar
  80. 80.
    Govindan SV, Cardillo TM, D’Souza CA et al. (2007) Therapy of human colonic and lung cancer xenografts with SN-38 conjugates of anti-CEACAM5 and anti-EGP-1 humanized monoclonal antibodies. Proc AACR-NCI-EORTC International Conference on molecular targets and cancer therapeutics, San Francisco, CA, October 22–26, 2007 (abstract C287)Google Scholar
  81. 81.
    Govindan SV, Moon SJ, Cardillo TM et al. (2008) Antibody-targeted chemotherapy of human colonic, lung, and pancreatic cancer xenografts with conjugates of topoisomerase I inhibitor, SN-38. Proc Sixth International Symposium on targeted anticancer therapies, Bethesda, MD, March 20–22, 2008 (abstract B06)Google Scholar
  82. 82.
    Chang C-H, Rossi E, Loo M et al. (2008) A modular method to prepare novel tetrameric cytokines, IFN, G-CSF, and EPO, with improved pharmacokinetics by the Dock-and-Lock (DNL) platform technology. Proc 2008 AACR Annual Meeting, San Diego, CA, April 12–16, 2008 (abstract 4906)Google Scholar
  83. 83.
    McDonagh CF, Turcott E, Westendorf L et al. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19:299–307CrossRefPubMedGoogle Scholar
  84. 84.
    Junutula JR, Raab H, Clark S et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932CrossRefPubMedGoogle Scholar
  85. 85.
    Winkler U, Barth S, Schnell R et al. (1997) The emerging role of immunotoxins in leukemia and lymphoma. Ann Oncol 8 (Suppl 1):139–146CrossRefPubMedGoogle Scholar
  86. 86.
    Hursey M, Newton DL, Hansen HJ et al. (2002) Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk Lymphoma 43:953–959PubMedGoogle Scholar
  87. 87.
    FitzGerald DJ, Kreitman R, Wilson W et al. (2004) Recombinant immunotoxins for treating cancer. Int J Med Microbiol 293:577–582CrossRefPubMedGoogle Scholar
  88. 88.
    Kreitman RJ (2006) Immunotoxins for targeted cancer therapy. AAPS J 8:E532–E551CrossRefPubMedGoogle Scholar
  89. 89.
    Newton DL, Hansen HJ, Mikulski SM et al. (2001) Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood 97:528–535CrossRefPubMedGoogle Scholar
  90. 90.
    Chang CH, Sapra P, Vanama SS et al. (2005) Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 106:4308–4314CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Immunomedics, Inc.Morris PlainsUSA
  2. 2.Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyBellevilleUSA

Personalised recommendations